When it comes to forced labor, there’s no middle path to navigate. Read More
As news broke of a successful trial of Pfizer and BioNTech’s vaccine on Monday morning, the reaction of epidemiologists and virologists came pouring in. Reader, they’re excited. Always a cautious bunch, scientists—so far, reaction skews European and U.K. heavy as the U.S. wakes up to the news—measured their words, but some, like Cambridge University’s Gordon […]
Superior morning, Ledger readers. I have been considering a query widely used in Silicon Valley investor circles a couple of years ago –“Are you currently a trait, product or company?” –and how it may apply to this glut of so-called challenger banks competing for U.S. clients. Challenger banks–some call them electronic banks neobanks–took {} years […]
